The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Diffuse large B-cell lymphoma with leukemic involvement.
 
Justin J. Kuhlman
No Relationships to Disclose
 
Muhamad Alhaj Moustafa
No Relationships to Disclose
 
Karan Seegobin
No Relationships to Disclose
 
Madiha Iqbal
No Relationships to Disclose
 
Ernesto Ayala
No Relationships to Disclose
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Allison Claire Rosenthal
No Relationships to Disclose
 
Jonas Paludo
Research Funding - Verily (Inst)
Other Relationship - Jazz Pharmaceuticals (Inst)
 
Ivana N. M. Micallef
No Relationships to Disclose
 
Patrick B. Johnston
No Relationships to Disclose
 
David James Inwards
Research Funding - Acerta Pharma (Inst)
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
 
Mohamed Kharfan-Dabaja
No Relationships to Disclose
 
Thomas E. Witzig
Consulting or Advisory Role - Abbvie/Genentech (Inst); ADC Therapeutics; Celgene (Inst); Cellectar; Epizyme; Incyte (Inst); Karyopharm Therapeutics; MorphoSys (Inst); Portola Pharmaceuticals; Seagen (Inst); Tessa Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group; Genentech (Inst); Kite/Gilead; MorphoSys (Inst); Selvita
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Han W. Tun
No Relationships to Disclose